Loading…
← CockpitCompetitor Analysis › 688428.SS InnoCare Pharma Ltd. Class AOpen in the cockpit ↗

InnoCare Pharma Ltd. Class A688428.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chinese biotech developing orelabrutinib, a BTK-inhibitor drug for blood cancers, plus a broader oncology/autoimmune pipeline.

≈ A Chinese BeiGene/Innovent, focused on BTK inhibitorsMomentum neutral 50
Mkt cap
$2.07B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$33.5M
20-day average traded
Fwd P/E
85.7×
forward earnings
ROIC−WACC
+19.9 pp
WACC 5.0%
Hurdle
-355 pp
Req g minus delivered
Next earnings
134 days
1 Apr 2027
Close · CNYCN¥23.31
1D-1.1%
1W-10.1%
1M-12.8%
3M-26.7%
6M-7.4%
YTD+13.6%
1Y-3.8%
ATR %5.9%
52w lowhigh33.4% off high

What InnoCare Pharma does

Chinese biotech developing orelabrutinib, a BTK-inhibitor drug for blood cancers, plus a broader oncology/autoimmune pipeline.

Sells orelabrutinib mainly in China, where hospital access and patient affordability depend on the national reimbursement list, which trades a negotiated lower price for much wider coverage. Autoimmune and cancer trials are paid for from sales, licensing deals and investor money. The company also has a Hong Kong listing alongside this Shanghai STAR Market line.

In one line: A Chinese BeiGene/Innovent, focused on BTK inhibitors.

Products and services

  • Orelabrutinib (BTK inhibitor)
  • Autoimmune/oncology pipeline

Customers

  • Hospitals/hematologists treating blood cancers

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • BTK inhibitors/hematology-oncology

What could go right

  • Blood-cancer and autoimmune drug demand

What could go wrong

  • Centralized procurement price cuts
  • Clinical/regulatory risk on pipeline

Moat: narrow (IP / patents, regulatory licence). Patent-protected, approved domestic BTK-inhibitor competing with imported drugs like ibrutinib.

Headquarters: Beijing, China · Founded: 2015 · Employees: 1,259

Named competitors

InnoCare Pharma at a glance

Size InnoCare Pharma (688428.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.07B, the 1134th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥23.31 on 18 Nov 2026.

Performance Over six months the shares fell 7.4%, against +2.8% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 21 in its peer set.

Growth Revenue grew 135.4% over the last twelve months (peer median +8.7%); the operating margin is 35.4% (peer median 14.7%).

Valuation It trades at 85.7× forward earnings against a peer median of 20.3× (most expensive of 17).

Price implies For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +344%, so the hurdle is -355 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 19.9 points above its cost of capital (5.0% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026Peer median 102688428.SS 95
Six months, rebased to 100: InnoCare Pharma against the median of its 20 peers (local-currency closes).

InnoCare Pharma financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.36BCN¥2.36BCN¥999MCN¥733MCN¥621M
Revenue growth—+136%+36%+18%—
Gross profitCN¥3.12BCN¥2.07BCN¥763MCN¥517MCN¥407M
EBITDAn/aCN¥571M-CN¥438M-CN¥609M-CN¥709M
Net incomeCN¥1.36BCN¥642M-CN¥441M-CN¥631M-CN¥887M
Free cash flowCN¥364MCN¥134M-CN¥310M-CN¥801M-CN¥763M
Capital expenditureCN¥132MCN¥70.2MCN¥78.2MCN¥255MCN¥370M
Total debtCN¥2.13BCN¥1.61BCN¥1.57BCN¥1.65BCN¥343M

Quarterly statements and history in the cockpit →

InnoCare Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%0%+20%H02600285214450603707603456300436009420ERIS600267600867BHVNAPLLTDONESOURCEHRMY60020145400512SHILPAMED603858ALIVUS688428.SS6-month return →1-month return →
Up and to the right = strong over both horizons. InnoCare Pharma is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%25×50×75×H02600285214450603707ERIS600267ONESOURCEHRMY6002014540SHILPAMED688428.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. InnoCare Pharma is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%H02600285214450ERIS688428.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. InnoCare Pharma is the large dot.

InnoCare Pharma competitors and peer comparison

Head to head with its named competitors (688428.SS vs 688235.SS vs ABBV vs AZN.L)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
InnoCare Pharma 688428.SS$2.07B-7%+135%35%85.7×-10.9%
BeOne Medicines 688235.SS$45.5B+9%+25%18%59.7×19.1%
AbbVie ABBV$506B+35%+11%36%18.1×-0.1%
AstraZeneca AZN.L$278B-2%+5%23%17.6×14.4%
Lilly (Eli) LLY$1.30T+36%+46%51%29.5×6.5%
Johnson & Johnson JNJ$656B+20%+8%26%24.2×3.7%

How InnoCare Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

InnoCare Pharma against its 20 peers (data as of 18 Nov 2026)
Measure688428.SSPeer medianRank in peer set
1-month return-12.8%+2.2%3rd lowest of 21
6-month return-7.4%+2.8%8th lowest of 21
Distance from 52-week high-33.4%-23.5%5th lowest of 21
Revenue growth (TTM)+135.4%+8.7%highest of 20
Operating margin35.4%14.7%2nd highest of 19
Forward P/E85.7×20.3×most expensive of 17
Growth the price implies (Req g, 7 yrs)-10.9%1.5%2nd least demanding of 15
Growth delivered (Del g)+344.2%+8.5%highest of 15
Hurdle (Req g minus delivered)-355.1 pp-4.7 ppleast demanding of 15
ROIC minus cost of capital+19.9 pp-0.5 pp4th highest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
InnoCare Pharma 688428.SSChina$2.07B-7%+135%35%85.7×-10.9%+344.2%
Haw Par H02.SISingapore$2.08B-25%-13%30%11.9×3.2%+15.7%
Henan Lingrui Pharmaceutial 600285.SSChina$2.04B+9%+5%22%15.9×-4.7%+10.6%
PharmaResearch 214450.KSSouth Korea$2.10B-24%+29%37%15.4×-11.0%+37.6%
Nanjing King-friend Biochemical Pharmaceutical 603707.SSChina$2.03B-3%+9%14%25.9×5.1%+6.4%
Zhejiang Jiuzhou Pharmaceutical 603456.SSChina$2.03B+19%-1%14%16.9×1.7%+15.7%
Fujian Cosunter Pharmaceutical 300436.SZChina$2.02B-45%0%-47%n/an/an/a
Hanall Biopharma 009420.KSSouth Korea$2.01B+12%+5%3%n/an/an/a
Eris Lifesciences ERIS.NSIndia$1.98B0%+11%26%27.9×26.3%+20.9%
Zhejiang Hisun Pharmaceutical 600267.SSChina$2.19B+14%-7%15%15.0×-9.7%-1.5%
Tonghua Dongbao Pharmaceutical 600867.SSChina$2.19B-12%+18%n/a25.4×0.9%+0.3%
Biohaven BHVNUnited States$1.95B+46%n/an/an/an/an/a
Alembic Pharmaceuticals APLLTD.NSIndia$2.20B+39%+20%12%25.0×26.7%+6.5%
OneSource Specialty Pharma ONESOURCE.NSIndia$1.95B-14%+11%6%44.6×n/an/a
Harmony Biosciences HRMYUnited States$1.94B+6%+20%22%8.6×-10.5%+40.3%
Jinyu Bio-Technology 600201.SSChina$1.93B-21%+22%10%59.0×23.4%-2.5%
Tsumura & 4540.TJapan$1.93B+6%+13%18%10.4×n/an/a
Grand Pharmaceutical 0512.HKHong Kong$1.93B-25%+7%13%9.4×1.2%+14.1%
Shilpa Medicare SHILPAMED.NSIndia$1.91B+94%+37%21%54.3×n/an/a
Shandong Buchang Pharmaceuticals 603858.SSChina$2.25B-7%+4%10%n/a-2.5%-5.8%
Alivus Life Sciences ALIVUS.NSIndia$1.90B+36%+8%31%23.8×20.1%+6.2%

Questions

Who are InnoCare Pharma's main competitors?
Named competitors: BeiGene (688235.SS), AbbVie (ABBV), AstraZeneca (AZN.L), Eli Lilly (LLY), Johnson & Johnson (JNJ). The cockpit's measured peer set (industry) also includes Haw Par (H02.SI), Henan Lingrui Pharmaceutial (600285.SS), PharmaResearch (214450.KS), Nanjing King-friend Biochemical Pharmaceutical (603707.SS), Zhejiang Jiuzhou Pharmaceutical (603456.SS), Fujian Cosunter Pharmaceutical (300436.SZ).
Is InnoCare Pharma expensive compared with its peers?
On forward p/e it trades at 85.7× against a peer median of 20.3×, most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +344%, so the hurdle is -355 pp: the price already allows for a slowdown.
How has InnoCare Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned -7.4% against +2.8% for the median peer; over one year -3.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.